Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France

Grégory Quéromès a,b,†, Grégory Destrass a,b,†, Antonin Bai a,b, Hadrien Regue b, Gwendolyne Burfin b,c, Solenne Brun b,c, Rémi Fanget b,c, Florence Morfin a,b, Martine Valette a,b,c, Sophie Trouillet-Assant a, Bruno Lina a,b,c, Emilie Frobert b and Laurence Josset a,b

aCIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Lyon, France; bLaboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, Lyon, France; cCentre National de Référence des virus des infections respiratoires, Lyon, France

ABSTRACT
During routine molecular surveillance of SARS-CoV-2 performed at the National Reference Center of Respiratory Viruses (Lyon, France) (n = 229 sequences collected February–April 2020), two frameshifting deletions were detected in the open reading frame 6, at the same position (27267). While a 26-nucleotide deletion variant (D26) was only found in one nasopharyngeal sample in March 2020, the 34-nucleotide deletion (D34) was found within a single geriatric hospital unit in 5/9 patients and one health care worker in April 2020. Phylogeny analysis strongly suggested a nosocomial transmission of D34, with potential fecal transmission, as also identified in a stool sample. No difference in disease severity was observed between patients hospitalized in the geriatric unit infected with WT or D34. In vitro D26 and D34 characterization revealed comparable replication kinetics with the wild-type (WT), but differential host immune responses. While interferon-stimulated genes were similarly upregulated after infection with WT and ORF6 variants, the latter specifically induced overexpression of 9 genes coding for inflammatory cytokines in the NF-κB pathway, including CCL2/MCP1, PTX3, and TNEa, for which high plasma levels have been associated with severe COVID-19. Our findings emphasize the need to monitor the occurrence of ORF6 deletions and assess their impact on the host immune response.

INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic triggered by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has continued to spread globally since its emergence in China in late 2019 [1,2]. Countries and localities have implemented various levels of public health mitigation measures with debatable success in an effort to control virus propagation [3–6]. The challenge in better understanding the fundamental characteristics of this novel virus includes the heterogeneous disease reports in conjunction with no clear treatments or vaccines yet available or approved [7–9]. Epidemiological tracking is paramount in the context of this current pandemic [10,11]. In particular, the genomic surveillance of circulating virus variants, such as with the seasonal epidemics of the influenza virus or even with the 2003 SARS epidemic, has brought useful information in understanding their respective evolutionary dynamics [12,13]. Recent tracking reports have discussed the high frequency and global distribution of a variant harbouring the D614G substitution located on the SARS-CoV-2 spike protein [14]. While higher infectious titre and increased protein stability have been associated with this variant, a clear fitness advantage has not been unequivocally established [15,16]. Historically, evolution of the related SARS-CoV virus is defined by deletion regions that impact the open-reading frames (ORF) of its genome [17,18]. Several deletions of large variations in size and prevalence have already been described in the SARS-CoV-2 genome [19–22].

The aim of this study was to therefore describe clinical patient data, viral replication capacity, and host innate immune modulation of two newly detected ORF6 deletion variants detected in early April from routine genomic surveillance of COVID-19 patients in Lyon, France.
Material and methods

Sequencing

Early routine genomic surveillance of SARS-CoV-2 in the National Reference Center (NRC) of Respiratory Viruses is based on daily random selection of samples with SARS-CoV-2 detected with quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) cycle threshold (Ct) <20 [6], which were then sequenced using an RNA metagenomic next-generation sequencing (mNGS) method previously described [19]. Briefly, viral genetic material contained in nasopharyngeal and stool samples was extracted by the EMAG* platform (bioMérieux, Lyon, FR). After DNase treatment (Life Technologies, Carlsbad, CA, USA), samples underwent random amplification using Whole Transcriptome Amplification (WT-A2 kit, Sigma-Aldrich, Darmstadt, DE) before sequencing on an Illumina NextSeqTM 550 with mid-output 2 × 150 flow cell. Importantly, the variants displaying an ORF6 deletion were confirmed by 3 other techniques, including capture- and amplicon-based strategies [23]. Sequencing of patient samples began on February 8th and is ongoing. For the stool sample, an amplicon-based approach developed by the ARTIC network (https://artic.network/ncov-2019) combined with Oxford Nanopore Technologies sequencing was used.

Phylogeny

Multiple sequence alignment was performed using the DECIPHER package in R [24]. Pairwise distances were computed using the Kimura (K80) model implemented in the function dist.dna, deleting the sites with missing data in a pairwise way. The phylogenetic tree was constructed using R software using ape package and the neighbour joining evolutionary method (hCoV19/Wuhan/IPBCAMSWH01/2019 as the root). CoV-GLUE resource [http://cov-glue.cvr.gla.ac.uk, [25]] was used to generate phylogenetic placement of the mutants, annotate the sequences, and check the prevalence of the deletions among worldwide sequences. Codon numbering is based on the Wuhan-Hu-1 sequence.

Virus replication kinetics

Replication kinetics was performed on both confluent buffalo green monkey (BGM) (BioWhittaker Europe) and human lung adenocarcinoma (CaLu-3) cells (ATCC® HTB-55™, Plateforme iPS, NeuroMyoGene Institute, Lyon, FR, [26]) at a multiplicity of infection (MOI) of 10^−3 at 36°C with 5% CO2 for 7 days, fully respecting the WHO interim biosafety guidance related to the coronavirus disease [27]. Comparative viral particle quantification of culture supernatant was performed by RdRp Institut Pasteur qRT-PCR on a QuantStudio™ 5 System (Applied Biosystems, ThermoFisher Scientific, MA, USA) with a standard curve after semi-automated EMAG* extraction (bio-Mérieux, Lyon, FR) [6]. Statistical analysis was performed by two-way ANOVA with Tukey multiple comparisons between both factors of comparison (virus variant and cell line) on GraphPad Prism (software version 8.4.3).

Immune-related gene expression profiling

Confluent CaLu-3 cells were inoculated in triplicate with wild-type or ORF6 deletion strains at 0.2 MOI and incubated for 24 h at 36°C with 5% CO2. For basal transcriptomic levels, a mock infection condition was also tested in triplicate. Cellular RNA extraction was performed with the RNeasy Mini Kit (Qiagen, DE) after supernatant removal and cell lysis directly in the culture vessel. Purified RNA was quantified with the Qubit RNA HS Kit (ThermoFisher Scientific, MA, USA). Host gene expression was evaluated using an 87-gene panel (Supplementary Table 1) with NanoString technology. Data treatment was performed using nSolver analysis software (version 4.0, NanoString Technologies). To normalize for differences in RNA input we used the geometric means over four housekeeping genes (DECR1, HPRT1, RPL19, and RPLP0).

Finally, the log2 fold change (log2 FC) between the infection conditions and the mock infection control were calculated to evaluate the transcriptomic modifications induced by SARS-CoV-2 strains. Criteria for differential expression were an absolute log2 FC of 1 and a q-value < 0.05 calculated using a Students’ t-test with subsequent Benjamini-Hochberg correction.

Ethics

Samples used in this study were collected as part of an approved ongoing surveillance conducted by the National Reference Center for Respiratory Viruses (NRC) in France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78–17 on 06 January 1978 and Décret 2019–536 on 29 May 2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was presented by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N°41).
Data availability

The SARS-CoV-2 genomes sequenced in this study were deposited on the GISAID database (https://www.gisaid.org/) on a regular basis, accession numbers can be found in Supplementary Table 2.

Results

ORF6 deletion variants detected during routine genomic surveillance

As part of the Auvergne-Rhône-Alpes (ARA) regional surveillance, 229 samples collected between 2 February and 12 April 2020 were sequenced by the French National Reference Center of Respiratory Viruses. These samples originated mainly from the Hospices Civils de Lyon (HCL) (149 sequences from 11 different hospital sites), with some from other hospitals in the Lyon area (24 sequences) and other regional hospitals (56 sequences, 12 cities).

Of these 229 samples, 6 sequences were shown to carry a 34-nt deletion (at position 27267–27300), henceforth denoted as D34, and 1 sequence a 26-nt deletion (at position 27267–27292), denoted as D26 (Figure 1). These deletions are both frameshifting deletions in the ORF6, starting at the same 27267 position after a stretch of 3 T at 27264–27266 (Figure 2). Because of the frameshifting, the D34 variant generates a premature stop codon (at position 27308, Wuhan-Hu-1 numbering), resulting in a presumed truncated 24 amino acid protein, instead of 61 in the wild-type (Wuhan-Hu-1 and all other sequences described yet). The D26 variant yields a 28 amino acid protein with its premature stop codon at position 27312. (Wuhan-Hu-1 numbering) (Figure 2(C)). These deletions have not yet been described on the CoV-GLUE resource, which lists all genomic variants in SARS-CoV-2 sequences available on the GISAID database (Supplementary Figure 1). Of note, D26 is annotated at different positions in CoV-GLUE to maximize amino acid alignment (27265–27290).

The 7 sequences carrying an ORF6 deletion belong to lineage B1, a lineage widely circulating in Europe (Supplementary Figure 1). There were between 0 and 3 SNP (Single Nucleotide Polymorphism) differences among D34 variants, for which 3/6 mutants displayed 1–3 SNPs, and between 2 and 4 SNPs between D26 and D34 variants (Supplementary Figure 2).

Evidence for direct transmission of the ORF6 34-nt deletion variant

The D34 samples were all collected from hospitalized patients or health care workers (HCW) in the same geriatric rehabilitation unit in the Hospices Civils de Lyon (GRU-3), between April 2nd and April 9th, while the sample with the 26-nt deletion was collected one month earlier (March 10th) in a geriatric unit of another hospital (Table 1). The hospitals are 80 km apart and there was no evidence for the transfer of patient #73 with the 26-nt deletion into GRU-3. To track the origin of the deletion, all patients hospitalized in the GRU-3 geriatric unit and all samples collected between March 18th and April 9th with high viral loads of SARS-CoV-2 (RT-PCR Ct value < 20) were sequenced (n = 9). In total, 44% (4/9 patients) were infected with the WT SARS-CoV-2 ORF6 (samples collected between March 18th–30th), with no read carrying the deletion at a minor frequency. Out of the 4 WT SARS-CoV-2 ORF6, three sequences were very similar to D34 and carried a G27289 T SNP (D30Y), which has already been identified in three patients from England between April 20th and 27th, 2020 (Figure 1). The other 55% (5/9 patients), in addition to 1 HCW, were infected with the 34-nt deletion (samples collected after April 2nd) with 100% of the reads carrying the deletion for each patient. Overall, 8/9 sequences of GRU-3, corresponding to those of the D34 variants and those of the three WT strains carrying the ORF6 G27289 T SNP were clustered together, while the sequence of the patient #38 was more divergent. We could not investigate whether the mutation spread within this unit after April 9th as only one COVID-19 patient was hospitalized in this geriatric unit since, for which their viral load (Ct > 30) was too low for mNGS.

34-nt ORF6 deletion variants yielded similar clinical presentations as WT ORF6 in hospitalized patients

Clinical data were studied on hospitalized patients in GRU-3 (i.e. excluding the HCW #63 to better control for confounding variables (e.g. age and comorbidities)) to compare COVID-19 severity between patients infected with D34 and with WT SARS-CoV-2 (n = 9) (Table 1). The median age of hospitalized patients was 87 years (ranging from 78 to 97), with 7 patients presenting at least cardiovascular disease as a risk factor (Table 1). Other comorbidities included hypertension (n = 5), obesity (n = 1), and chronic obstructive pulmonary disease (n = 1).

Clinical presentations of hospitalized patients with the D34 variants (n = 5) were classified as asymptomatic for one patient, upper respiratory tract infection (URTI) for 2 patients, and lower respiratory tract infection (LRTI, pneumonia) for 3 patients. To evaluate disease severity in relation to the D34 deletion, mild (asymptomatic and URTI, n = 5) versus severe COVID-19 (LRTI, n = 4) was compared by Fisher’s exact test. No significant difference in clinical presentation could be observed between hospitalized patients harbouring or not the ORF6 deletion (p > 0.999).

From the five hospitalized patients harbouring D34 deletion, 2 died from COVID-19 infection, all presenting
LRTI and comorbidities. One patient (#25) died at day 5 after diagnosis, but their death was not related to COVID-19 infection but to septicemia. To evaluate disease outcome in relation to the D34 deletion, death from COVID-19 versus favorable outcome (including non-COVID-19 death) was compared by Fisher’s exact test. No significant difference in disease outcome could be observed between hospitalized patients harbouring or not the D34 deletion ($p = 0.44$).

Notably, patient #47 harbouring a D34 variant was still positive after 14 days in respiratory and stool samples. Virus present in the stool was 100% identical to the first virus sequenced from respiratory samples. Unfortunately, the respiratory sample at day 14 could not be sequenced due to $\text{Ct} > 30$.

**SARS-CoV-2 deletion variants yield comparable replication kinetics to reference strain**

Two genomes representative of ORF6 deletion variants found in this regional circulation were selected for replication tests: hCoV-19/France/ARA22647/2020 (EPI_ISL_508919; D34 variant) and hCoV-19/France/ARA0731/2020 (EPI_ISL_508941; D26 variant).
These genomes were compared against the reference genome hCoV-19/France/ARA24023/2020 (EPI_ISL_508931; devoid of any deletions), which was the most similar isolated variant sequenced available in the laboratory at the time of the investigation. The reference genome had 1–3 SNPs compared with D26 and D34 variants (Supplementary Figure 2).

Replication kinetics measured by viral genome quantification revealed no significant difference between the three variants throughout the course of in vitro infection on both BGM and CaLu-3 cell lines (Figure 3). However, a significant difference was observed between cell lines for each variant, with an increased level of replication on BGM (as early as 24 h post-inoculation). More specifically, viral replication spiked rapidly on BGM cells within the first 48 h, before reaching a plateau at 72 h. Conversely, viral replication on CaLu-3 cells rose steadily within the first 48 h, before reaching a plateau at 96 h. Of interest, a 2-log difference was observed for maximum genome quantification between BGM and CaLu-3, with an average of 5.76 \times 10^{12} and 4.01 \times 10^{10} copies/mL, respectively.

**Differential immune gene expression from ORF6 deletion SARS-CoV-2 infection**

As ORF6 codes for a protein involved in innate immunity regulation, we aimed to explore the impact of D34 and D26 on the immune transcriptome at 24 h post-infection. Of the 87 human host immune genes tested on the Nanostring Immunity panel, 40 were significantly upregulated following infection by WT SARS-CoV-2 compared to the mock infection on CaLu-3 cells (Supplementary Figure 3, Supplementary Table 2). These upregulated genes belong to the following pathways: inflammation mediation by chemokine and cytokine signalling, interleukin signalling, toll receptor signalling, and apoptosis signalling. BST2, CXCL10/IP10, IDO1, and ZBP1 presented the highest upregulation with 4.32, 4.89, 4.16, and 5.05 log2FC, respectively (Figure 4(A)). Interestingly, there was no difference of their expression with the deletion variants, as well as for certain interferon-stimulated genes (ISG), including IFI27, IFI35, IFI44L, IFIH1/MDA5, IFITM1, IL18R1, and STAT2 (Figure 4(A)). However, an enhanced upregulation of 9 genes, all involved in the NF-κB pathway (CCL2/MCP1, CCL20, CCL4, CXCL2/MIP2α, IL1A, NFKBIA, PTX3, TNFA, TNFAIP3), was observed after infection with D26 variants, in comparison to the WT (Figure 4(B)). While higher levels of expression of these cytokines were also noted after infection with the D34 variant compared with WT, increased expression did not reach statistical significance after multi-test correction (q-value < 0.05), with the exception of CCL20. Of note, the D26 variant induced a markedly higher level of expression for 6 of these 9 genes (CCL2/MCP1, CCL20, CCL4, IL1A, PTX3, TNFA) than the D34 variant.
Table 1. Clinical data from patients infected with the D34 ORF6 deletion variant compared with related patients infected with WT SARS-CoV-2.

| Sequence name | Age (years) | Sex | Comorbidities | Respiratory manifestations | Hospitalization (Yes / No) | Hospitalization Unit | ORF6 deletion | Date of diagnosis | Duration of excretion | Outcome |
|---------------|-------------|-----|---------------|---------------------------|---------------------------|----------------------|---------------|------------------|----------------------|---------|
| ARA10968/2020 | 89          | F   | Hypertension  | URTI                      | Yes                       | GRU-3                | None          | 2020/03/18       | Respiratory sample positive at D21 | Favorable |
| ARA12238/2020 | 78          | M   | None          | LRTI                      | Yes                       | GRU-3                | None          | 2020/03/22       | Not monitored         | Favorable |
| ARA13746/2020 | 84          | F   | Cardiovascular disease, Hypertension | LRTI                      | Yes                       | GRU-3                | None          | 2020/03/25       | Respiratory sample positive at D14 | Favorable |
| ARA16665/2020 | 89          | M   | Cardiovascular disease, Hypertension | Asymptomatic              | No                        | GRU-3                | None          | 2020/03/30       | Not monitored         | Favorable |
| ARA18625/2020 | 97          | F   | Cardiovascular disease, Hypertension, Obesity | LRTI                      | Yes                       | GRU-3                | D34           | 2020/04/02       | Respiratory sample positive at D14 | Favorable |
| ARA2068/2020  | 82          | M   | Cardiovascular disease, Hypertension | Asymptomatic              | Yes                       | GRU-3                | D34           | 2020/04/04       | Respiratory sample positive at D14 | Favorable |
| ARA21163/2020 | 31          | F   | Cardiovascular disease, Hypertension | URTI                      | No                        | GRU-3                | D34           | 2020/04/06       | Respiratory sample positive at D14 | Favorable |
| ARA21360/2020 | 94          | M   | Cardiovascular disease, Hypertension | URTI                      | Yes                       | GRU-3                | D34           | 2020/04/07       | Respiratory sample positive at D14 | Favorable |
| ARA22647/2020 | 81          | F   | Cardiovascular disease | LRTI                      | Yes                       | GRU-3                | D34           | 2020/04/09       | Respiratory sample positive at D14 | Favorable |
| ARA22650/2020 | 85          | F   | Cardiovascular disease | Not specified             | Yes                       | GRU-3                | D34           | 2020/04/09       | Respiratory and stool samples positive at D14 | Deceased from COVID-19 (D9) |

HCW = health care worker; COPD = chronic obstructive pulmonary disease; URTI: Upper Respiratory Tract Infection; LRTI: Lower Respiratory Tract Infection; HCL = Hospices Civils de Lyon; GRU-3 = geriatric rehabilitation unit within HCL; D26 = 26-nt deletion; D34 = 34-nt deletion; D = Day.

aSequence names in the table are preceded by hCoV-19/France/; example: hCoV-19/France/ARA10968/2020.

bDuration of excretion and death are calculated from the date of diagnosis.
This difference was not due to higher replication of D26, as equivalent viral quantification was observed at 24 h for all conditions, with an average of 7.94 log₁₀ copies/mL. Altogether, these results show that D26 and D34 do not impact ISG expression but may increase NFKB-driven inflammatory genes, and with a higher magnitude for D26.

Discussion

Despite reports of the relative stability of the SARS-CoV-2 genome within the human population, whole genome sequencing has revealed recurrent variants with variable mutation patterns over the course of the pandemic and within distinct geographic regions [10,19,28–31]. Here, we characterized large ORF6 deletion variants identified through surveillance of patients from the same hospital unit. Reports of similar patterns of genomic deletions in the SARS-CoV-2 genome since its emergence have already been described, including in the ORFs 6, 7, and 8 [20,21,29,32].

The origin of the D34 deletion is still unknown. However, as the WT virus isolated from GRU-3 patients were genetically close to the D34 variants, the GRU-3 patients infected by the WT virus in March could have been the initial source of the D34 deletion. None of the GRU-3 patients with WT or deletion variants presented any intra-host diversity in the ORF6 deletion region that would have been indicative of a recent mutation or recombination. Nevertheless, the D34 variants’ introduction since April 2nd with its limited presence in the hospital unit thereafter and the clustering of the corresponding whole genome sequences by phylogeny analysis strongly suggest a nosocomial transmission of the D34 variant. Importantly, the persistence of the same D34 consensus sequence in a patient’s stool sample 14 days after diagnosis from a nasopharyngeal sample gives emphasis to the enteric tropism capacity of D34 variants and the potential contribution of fecal transmission to nosocomial transmission [33].

The normal rate of mutation of SARS-CoV-2 has been reported at about 2.5 mutations per month.
Given that D34 variants had 1–3 SNP differences between consensus sequences of D34 variants collected between one week, a higher mutation rate than normal might be linked to adaptive mutations following the deletion. During the revisions of the manuscript, 3 novel sequences of the D34 variant sampled in May at the university hospital of Lyon (EPI_ISL_683361; EPI_ISL_683360; EPI_ISL_683354) and 1 sequence of the D26 variant sampled on April 23rd in a hospital located 75 km from Lyon (EPI_ISL_660432) were detected out of the 932 viruses sequenced to date in our laboratory. This suggests a relatively limited diffusion of these variants. Nevertheless, the importance of such genomic deletion variants by NGS investigation during the evolution of disease transmission and population prevalence should not be overlooked [13,36,37]. Evidence of adaptation by means of genomic deletions during the middle and late phases of the SARS-CoV 2003 epidemic has been tenuously described [17,18,38–40].

As research on the SARS-CoV ORF6 has attributed this accessory protein (p6) with potential functions of intracellular membrane rearrangements, of interferon induction inhibition, and of replication stimulation [41–43], we performed a global in vitro characterization of the ORF6 variants. Firstly, no significant impact was noted on replication capacity in vitro in comparison to a wild-type strain, in two different cell lineages. The comparable replication kinetics between wild-type and deletion variants determined in vitro is supported by the congruent in vivo replication capacity with the latter being assessed by RT–PCR from diagnosis (Ct < 20).

Secondly, we investigated whether the ORF6 variants could modulate innate immune responses. The important upregulation of certain genes induced by a SARS-CoV-2 infection observed in the present study were in accordance with typical antiviral restriction responses, such as BST2, IDO, and IFTM1 [44–46]. Focusing on the two deletion variants, the expression of interferon-stimulated genes (ISG) was not differentially expressed in comparison with the WT virus, suggesting that the resulted truncated proteins from the two ORF6 deletions did not impact this signalling pathway. This is in contrast to previous findings of interferon pathway dysregulation via STAT1/STAT2 nuclear translocation blocking by the p6 protein [47] Nevertheless, our transcriptomic
analyses revealed an enhanced upregulation of 9 immune-related genes in the NF-κB pathway, including those coding for inflammatory cytokines such as chemokines, IL1A and TNFa, specifically induced by the infection of partial ORF6 deletions. These findings suggest that the p6 protein would interact in an antagonistic manner to suppress their antiviral properties. Recent literature confirms this inhibitory function of the SARS-CoV-2 p6 protein [48–50]. Of interest, the D26 variant, which resulted in a longer protein sequence in silico than for the D34 variant, presented an even higher upregulation of these NFKB-driven inflammatory genes. It can be hypothesized that D26 yields a complete loss of function of p6, perhaps due to the additional histidine residues in close proximity to the α-helix, while D34 may lead to a p6 with a somewhat conserved activity. A 27-nt in-frame ORF6 deletion in proximity to D34 and D26 (at position 27264–27290) selected during passaging on Vero6 cells had important three-dimensional structural alterations to the protein [32].

Most importantly, high plasma levels of PTX3, MCP1, and TNFa in COVID-19 patients have been described as early molecular indicators of adverse disease progression needing intensive care [7,51]. In addition, within the context of cytokine storms from acute respiratory syndromes, high plasma levels of CCL2, CXCL10, and TNFa have also been reported [48,52]. Consequently, the enhanced expression of CCL2/MCP1, PTX3 and TNFa observed after infection with D26 could indicate a heightened disease risk from an NF-κB-driven inflammatory response by an ORF6 deletion variant [53]. Although there was no significant difference in disease severity between patients at the GRU-3 hospital unit harbouring D34 ORF6 variant or WT, the small number of patients may have hindered the observation of an increased virulence potential of the deletion variant. In addition, the patient infected by the D26 variant is omitted from our analysis as no clinical data was available. Finally, we could not validate the enhanced expression of inflammatory cytokines in patients as plasma samples were not available in this retrospective cohort.

Taken together, these findings suggest that ORF6 deletion variants could play a major role in the inflammatory host-response, without impacting virus replication. Our study underlines the need to investigate how ORF6 deletions can impact host-response and clinical outcome, particularly since whole genome sequence analysis on the CoV-GLUE database has revealed converging clusters of similar ORF6 deletions mainly in Utah, USA and England, UK. Additional genomic and structural investigations are needed to explore the impact of ORF6 deletions, in terms of ribosomal frameshift stimulators, RNA translation production ratios, innate host immunity modulation, and clinical outcomes. The integration of more fundamental research dedicated to elucidating the factors that impact SARS-CoV-2 replication, transmission, and disease progression will ultimately help translational projects to advance the fight against the current COVID-19 pandemic.

Acknowledgments
We would like to thank all the patients, laboratory technicians, and clinicians who contributed to this investigation. We gratefully acknowledge all the members of CoV-GLUE, Nextstrain.org, and virological.org for sharing their analysis in real time.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This study was in part funded by the French National Research Agency [Agence Nationale de la Recherche] under Grant ANR-20-COVI-0064.

ORCID
Grégory Quéromès https://orcid.org/0000-0001-8176-3955

References
[1] Guo G, Ye L, Pan K, et al. New insights of emerging SARS-CoV-2: epidemiology, etiology, clinical features, clinical treatment, and prevention. Front Cell Dev Biol. 2020;8:Art. no. 410.
[2] Srivastava N, Baxi P, Ratho RK, et al. Global trends in epidemiology of coronavirus disease 2019 (COVID-19). Coronavirus Dis 2019 COVID-19. 2020:9–21.
[3] Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020:25:23–30.
[4] Korean Society of Infectious Diseases, Korean Society of Pediatric Infectious Diseases, Korean Society of Epidemiology, et al. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35(10):e112.
[5] Lee VJ, Chiew CJ, Khong WX. Interrupting transmission of COVID-19: lessons from containment efforts in Singapore. J Travel Med. 2020;27:3.
[6] Ettievant S, Bal A, Escuret V, et al. Performance assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories. J Clin Med. 2020;9:1871.
[7] Huang C, Wang Y, Li X, et al. Clinical features of coronavirus disease 2019 in Wuhan, China. Lancet. 2020;395:497–506.
[8] Lescure F-X, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20:697–706.
[9] El-Aziz TMA, Stockand JD. Recent progress and challenges in drug development against COVID-19
coronavirus (SARS-CoV-2) – an update on the status. Infect Genet Evol. 2020;83:104327.

[10] Yang H-C, Chen C, Wang J-H, et al. Genomic, geographic and temporal distributions of SARS-CoV-2 mutations. bioRxiv [Internet]. [cited 2020 Jun 3]. Available from: https://www.biorxiv.org/content/10.1101/2020.04.22.055863v1.

[11] Gámbaro F, Behillil S, Baidaliuk A, et al. Introductions and early spread of SARS-CoV-2 in France, 24 January to 23 March 2020. Eurosurveillance. 2020;25:2001200.

[12] Baillie GJ, Galiano M, Agapow P-M, et al. Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol. 2012;86:11–18.

[13] Poon LLM, Song T, Rosenfeld R, et al. Quantifying influenza virus diversity and transmission in humans. Nat Genet. 2016;48:195–200.

[14] Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;81:104260.

[15] Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812–827.

[16] Zhang L, Jackson CB, Mou H, et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv [Internet]. [cited 2020 Jul 27]. Available from: https://www.biorxiv.org/content/10.1101/2020.06.12.148726v1.

[17] Chiu RWK, Chim SSC, Tong Y, et al. Tracing SARS-coronavirus variant with large genomic deletion. Emerg Infect Dis. 2005;11:168–170.

[18] Muth D, Corman VM, Roth H, et al. Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human–to–human transmission. Sci Rep. 2018;8:15177.

[19] Bal A, Destrass G, Gaymard A, et al. Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del). Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2020;26:960–962.

[20] Su YCF, Anderson DE, Young BE, et al. Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2. mBio. 2020;11(4).

[21] Holland LA, Kaelin EA, Maqsood R, et al. An 81-nucleotide deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (January to March 2020). J Virol. 2020;94(14).

[22] Lau S-Y, Wang P, Mok BW-Y, et al. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg Microbes Infect. 2020;9:837–842.

[23] Charre C, Giveva C, Sabatier M, et al. Evaluation of NGS-based approaches for SARS-CoV-2 whole-genome characterisation, bioRxiv [Internet]. [cited 2020 Jul 20]. DOI:10.1101/2020.07.14.201947

[24] R Core Team. R: A language and environment for statistical computing [Internet]. R Computing Foundation for Statistical Computing; 2013. Available from: http://www.R-project.org/.

[25] Singer JB, Thomson EC, McLauchlan J, et al. GLUE: a flexible software system for virus sequence data. BMC Bioinform. 2018;19:Art. no. 532.

[26] Perucho M, Goldfarb M, Shimizu K, et al. Human-tumor-derived cell lines contain common and different transforming genes. Cell. 1981;27:467–476.

[27] World Health Organization. Laboratory biosafety guidance related to coronavirus disease (COVID-19): interim guidance, 13 May 2020; 2020 [cited 2020 Jul 17]. Available from: https://apps.who.int/iris/handle/10665/332076.

[28] Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18:Art. no. 179.

[29] Batty EM, Kochakarn T, Panthan B, et al. Genomic surveillance of SARS-CoV-2 in Thailand reveals mixed imported populations, a local lineage expansion and a virus with truncated ORF7a. medRxiv [Internet]. [cited 2020 Jun 4]. Available from: https://www.medrxiv.org/content/10.1101/2020.05.22.20108498v1.

[30] Chrisman B, Paskov K, Stockham N, et al. Common microdeletions in SARS-CoV-2 sequences [Internet]. Virological. 2020. Available from: https://virological.org/t/common-microdeletions-in-sars-cov-2-sequences/485.

[31] Alm E, Broberg EK, Connor T, et al. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European region, January to June 2020. Eurosurveillance. 2020;25(32).

[32] Riajas MA, Frank AM, Puthucheary NP, et al. A rare deletion in SARS-CoV-2 ORF6 dramatically alters the predicted three-dimensional structure of the resultant protein [Internet]. Cold Spring Harbor Laboratory. 2020 [cited 2020 Aug 5]. Available from: https://www.biorxiv.org/content/10.1101/2020.06.09.134460v1.

[33] Shi J, Sun J, Hu Y. Enteric involvement of SARS-CoV-2: Implications for the COVID-19 management, transmission, and infection control. Virulence. 2020;11:941–944.

[34] Duchene S, Featherstone L, Haritopoulou-Sinanidou M, et al. Temporal signal and the phylogenetic threshold of SARS-CoV-2. bioRxiv [Internet]. Available from: https://www.biorxiv.org/content/10.1101/2020.05.04.077735v1.

[35] Day T, Gandon S, Lion S, et al. On the evolutionary epidemiology of SARS-CoV-2. Curr Biol. 2020;30:R849–R857.

[36] Oude Munnink BB, Nieuwenhuijse DF, Steen M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. Nat Med. 2020;26:1405–1410.

[37] McHardy AC, Adams B, Manchester M. The role of genomics in tracking the evolution of influenza A virus. Plos Pathog. 2009;5:e1000566.

[38] Keng C-T, Tan Y-J. Molecular and biochemical characterization of the SARS-CoV accessory proteins ORF8a, ORF8b and ORF8ab. Mol Biol SARS-CoV-2. 2009:177–191.

[39] Liu W, Tang F, Fontanet A, et al. Molecular Epidemiology of SARS-associated coronavirus, Beijing. Emerg Infect Dis. 2005;11:1420–1424.

[40] Zhao G. SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Philos Trans R Soc B Biol Sci. 2007;362:1063–1081.

[41] Gunalan V, Mirazimi A, Tan Y-J. A putative diacidic motif in the SARS-CoV ORF6 protein influences its subcellular localization and suppression of expression of co-transfected expression constructs. BMC Res Notes. 2011;4:446.

[42] Geng H, Liu Y-M, Chan W-S, et al. The putative protein 6 of the severe acute respiratory...
syndrome-associated coronavirus: expression and functional characterization. FEBS Lett. 2005;579:6763–6768.

[43] Kopecky-Bromberg SA, Martínez-Sobrido L, Frieman M, et al. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81:548–557.

[44] Mahauad-Fernandez WD, Okeoma CM. The role of BST-2/tetherin in host protection and disease manifestation. Immun Inflamm Dis [Internet]. 2015 [cited 2020 Nov 27];4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768070/.

[45] Lepiller Q, Soulier E, Li Q, et al. Antiviral and immunoregulatory effects of Indoleamine-2,3-dioxygenase in hepatitis C virus infection. J Innate Immun. 2015;7:530–544.

[46] Bailey CC, Zhong G, Huang I-C, et al. IFITM-family proteins: the cell’s first line of antiviral defense. Annu Rev Virol. 2014;1:261–283.

[47] Miorin L, Kehrer T, Sanchez-Aparicio MT, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci. 2020;117:28344–28354.

[48] Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32.

[49] Li J-Y, Liao C-H, Wang Q, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074.

[50] Yuen C-K, Lam J-Y, Wong W-M, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9:1418–1428.

[51] Schirinzi A, Pesce F, Laterza R, et al. Pentraxin 3: potential prognostic role in SARS-CoV-2 patients admitted to the emergency department. J Infect [Internet]. 2020 [cited 2020 Nov 22]. Available from: https://www.journalofinfection.com/article/S0163-4453(20)30687-3/abstract.

[52] Castelli V, Cimini A, Ferri C. Cytokine storm in COVID-19: “when you come out of the storm, you won’t be the same person who walked in”. Front Immunol [Internet]. 2020 [cited 2020 Nov 27];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492381/.

[53] Hadjadj J, Yatim N, Barnabei I, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724.